Liquidia and Pharmosa Biopharm announced that they have entered into an exclusive licensing agreement for the development and commercialization in North America of L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease, or PH-ILD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LQDA:
- Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
- Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
- Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
- Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference